In addition to this, antibody-modified graphene field-effect transistor (GFET)-based label-free biosensors have been used to target cancer cells through non-covalent modifications, where GFET modified with carcinoembryonic antigen (Anti-CEA) monitors the reaction between CEA and anti-CEA proteins. Here, CEACAM5 is linked to cancer.